https://www.biopharmawatch.com/news/ISPC/ispecimen-closes-5-million-public-offering BiopharmaWatch en 2026-08-07T20:30:00.000Z iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/INCY/incyte-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-08-07T20:30:00.000Z Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SRRK/scholar-rock-fda-review-apitegromab-sma BiopharmaWatch en 2026-08-07T20:20:00.000Z Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-07T20:08:14.609Z Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/BRVE/braveheart-bio-upsized-ipo-2026 BiopharmaWatch en 2026-08-07T20:05:00.000Z Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/ENTX/entera-announces-q2-2026-results-business-updates BiopharmaWatch en 2026-08-07T20:05:00.000Z Entera Announces Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/ATYR/atyr-pharma-q2-2026-results-efzofitimod-prioritization BiopharmaWatch en 2026-08-07T20:01:00.000Z aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-conference-call-fda-review BiopharmaWatch en 2026-08-07T20:01:00.000Z NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-250000-convertible-note-financing BiopharmaWatch en 2026-08-07T20:01:00.000Z IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing https://www.biopharmawatch.com/news/GRAL/grail-fda-advisory-meeting-galleri-test-review BiopharmaWatch en 2026-08-07T15:05:00.000Z GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test https://www.biopharmawatch.com/news/FEMY/femasys-secures-30-million-private-placement BiopharmaWatch en 2026-08-07T13:25:00.000Z Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million https://www.biopharmawatch.com/news/RCEL/avita-medical-participation-canaccord-genuity-conference BiopharmaWatch en 2026-08-07T12:45:00.000Z AVITA Medical Announces Participation at Canaccord Genuity Growth Conference https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T12:45:00.000Z Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-q2-2026-results-dnase-platform BiopharmaWatch en 2026-08-07T12:35:00.000Z Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q2-2026 BiopharmaWatch en 2026-08-07T12:30:00.000Z Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-1-study-nbip-1968-obesity BiopharmaWatch en 2026-08-07T12:30:00.000Z Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q2-2026-results-report BiopharmaWatch en 2026-08-07T12:00:00.000Z Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-q2-2026-results-cypath-lung BiopharmaWatch en 2026-08-07T12:00:00.000Z bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung https://www.biopharmawatch.com/news/HUMA/humacyte-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-07T12:00:00.000Z Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 https://www.biopharmawatch.com/news/LFWD/lifeward-report-q2-2026-results-august-14 BiopharmaWatch en 2026-08-07T12:00:00.000Z Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026 https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-presents-pk-pd-modeling-piktor-trial BiopharmaWatch en 2026-08-07T11:30:00.000Z Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference https://www.biopharmawatch.com/news/SNGX/soligenix-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-07T11:30:00.000Z Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-q2-2026-results BiopharmaWatch en 2026-08-07T11:05:00.000Z Treace Medical Concepts Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T11:00:00.000Z Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/NHC/nhc-reports-second-quarter-2026-earnings BiopharmaWatch en 2026-08-07T11:00:00.000Z NHC Reports Second Quarter 2026 Earnings https://www.biopharmawatch.com/news/NRXP/fda-first-cycle-review-preservative-free-ketamine BiopharmaWatch en 2026-08-07T11:00:00.000Z FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-07T11:00:00.000Z Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T11:00:00.000Z Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q2-2026-results BiopharmaWatch en 2026-08-07T11:00:00.000Z Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-record-q2-2026-results BiopharmaWatch en 2026-08-07T10:50:00.000Z ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NHC/nhc-announces-common-dividend BiopharmaWatch en 2026-08-07T00:00:00.000Z NHC Announces Common Dividend https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-executive-chair-transition BiopharmaWatch en 2026-08-06T22:24:00.000Z Tango Therapeutics Announces Executive Chair Transition https://www.biopharmawatch.com/news/BIIB/biogen-acquisition-raythera-immunology-assets BiopharmaWatch en 2026-08-06T22:15:00.000Z Biogen Completes Acquisition of RayThera Inc. https://www.biopharmawatch.com/news/NUTX/nutex-health-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-06T21:58:00.000Z NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-needham-conference BiopharmaWatch en 2026-08-06T21:15:00.000Z LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-06T21:05:30.769Z Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/ACRS/aclaris-fast-track-modzatinib-lichen-planus BiopharmaWatch en 2026-08-06T21:04:33.797Z Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) https://www.biopharmawatch.com/news/RMD/resmed-q4-fy2026-results BiopharmaWatch en 2026-08-06T21:01:05.826Z Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:58:43.642Z ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/NEPH/nephros-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:58:29.644Z Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/CTMX/cytomx-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-06T20:57:55.220Z CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/OCS/oculis-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:57:09.775Z Oculis Reports Q2 2026 Financial Results and Provides Company Update https://www.biopharmawatch.com/news/ICUI/icu-medical-q2-2026-results-guidance-update BiopharmaWatch en 2026-08-06T20:56:28.385Z ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance https://www.biopharmawatch.com/news/ORGO/organogenesis-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:56:14.642Z Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:55:58.991Z Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-q2-2026-results BiopharmaWatch en 2026-08-06T20:55:01.545Z Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-06T20:48:07.303Z Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/INAB/in8bio-reports-q2-2026-results-highlights BiopharmaWatch en 2026-08-06T20:47:08.109Z IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-06T20:46:15.827Z Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/REPL/fda-accelerated-approval-tudriqev-melanoma BiopharmaWatch en 2026-08-06T20:45:32.133Z Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen https://www.biopharmawatch.com/news/APYX/apyx-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:44:09.042Z Apyx Medical Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CVRX/cvrx-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:43:53.232Z CVRx Reports Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CON/concentra-group-holdings-q2-2026-results BiopharmaWatch en 2026-08-06T20:31:00.000Z Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance https://www.biopharmawatch.com/news/MGTX/meiragtx-inducement-grant-nasdaq-listing-rule-5635c4 BiopharmaWatch en 2026-08-06T20:30:32.000Z MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:30:00.000Z Cellectis Reports Financial Results for the Second Quarter 2026 https://www.biopharmawatch.com/news/CTSO/cytosorbents-q2-2026-financial-results-regulatory-update BiopharmaWatch en 2026-08-06T20:25:00.000Z CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-06T20:15:33.000Z X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:15:00.000Z Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/GMED/globus-medical-reports-q2-2026-results BiopharmaWatch en 2026-08-06T20:15:00.000Z Globus Medical Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/AMN/amn-healthcare-q2-2026-results BiopharmaWatch en 2026-08-06T20:15:00.000Z AMN HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS https://www.biopharmawatch.com/news/PROF/profound-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:12:00.000Z Profound Medical Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SLDB/solid-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:08:00.000Z Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-06T20:06:17.000Z Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:57.000Z Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-q2-2026-results-highlights BiopharmaWatch en 2026-08-06T20:05:56.000Z Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-business-updates-q2-2026 BiopharmaWatch en 2026-08-06T20:05:00.000Z Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARDX/ardelyx-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ALEC/alector-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Alector Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SGP/spyglass-pharma-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ECOR/electrocore-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z electroCore Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q2-2026-financial-results-updates BiopharmaWatch en 2026-08-06T20:05:00.000Z Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates https://www.biopharmawatch.com/news/SRZN/surrozen-reports-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/EVMN/evommune-reports-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-06T20:05:00.000Z Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Puma Biotechnology Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NTRA/natera-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Natera Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance https://www.biopharmawatch.com/news/WGS/genedx-participate-upcoming-investor-conferences BiopharmaWatch en 2026-08-06T20:05:00.000Z GeneDx to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/OABI/omniab-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Tandem Diabetes Care Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PRTA/prothena-reports-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Prothena Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Hyperfine, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z TriSalus Life Sciences Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/INGN/inogen-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Inogen Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ASTH/astrana-health-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Astrana Health, Inc. Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/AORT/artivion-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Artivion Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MTVA/metavia-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/QDEL/quidelortho-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z QuidelOrtho Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SI/shoulder-innovations-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:05:00.000Z Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 https://www.biopharmawatch.com/news/CYRX/cryoport-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Cryoport Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ZYME/zymeworks-corporate-update-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OMDA/omada-health-q2-2026-results-ceo-transition BiopharmaWatch en 2026-08-06T20:03:00.000Z Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition https://www.biopharmawatch.com/news/HCAT/health-catalyst-sale-vitalware-focus-healthcare-intelligence BiopharmaWatch en 2026-08-06T20:03:00.000Z Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:03:00.000Z BioLife Solutions Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/JANX/janux-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:02:00.000Z Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TXG/10x-genomics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:02:00.000Z 10x Genomics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RCEL/avita-medical-q2-results-revenue-guidance BiopharmaWatch en 2026-08-06T20:02:00.000Z AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven https://www.biopharmawatch.com/news/AGMB/agomab-half-year-2026-financial-results-outlook BiopharmaWatch en 2026-08-06T20:01:30.000Z Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook https://www.biopharmawatch.com/news/VYGR/voyager-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Voyager Reports Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q2-2026-results-pipeline-progress BiopharmaWatch en 2026-08-06T20:01:00.000Z Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Maravai LifeSciences Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-closes-credit-facility-27-5-million BiopharmaWatch en 2026-08-06T20:01:00.000Z Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital https://www.biopharmawatch.com/news/ASND/ascendis-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-06T20:01:00.000Z Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 https://www.biopharmawatch.com/news/OM/outset-medical-reports-q2-2026-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Outset Medical Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CLDX/celldex-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:01:00.000Z Celldex Reports Second Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q2-2026 BiopharmaWatch en 2026-08-06T20:01:00.000Z Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:01:00.000Z SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/XENE/xenon-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Xenon Reports Q2 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-q2-2026-results BiopharmaWatch en 2026-08-06T20:01:00.000Z NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ONC/beone-medicines-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:00:00.000Z شركة BeOne Medicines تعلن عن النتائج المالية للربع الثاني من عام 2026 وآخر مستجدات الأعمال https://www.biopharmawatch.com/news/INMB/inmune-bio-q2-2026-results-regulatory-progress BiopharmaWatch en 2026-08-06T20:00:00.000Z INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress